利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.018 秒)

    BISPECIFIC ANTIBODY
    4.
    发明公开
    BISPECIFIC ANTIBODY 审中-公开

    公开(公告)号：EP3763743A1

    公开(公告)日：2021-01-13

    申请号：EP19751922.6

    申请日：2019-02-08

    申请人： ONO Pharmaceutical Co., Ltd.

    发明人： SHIBAYAMA, Shiro ,  SHIMBO, Takuya ,  TEZUKA, Tomoya ,  THROSBY, Mark ,  DE KRUIF, Cornelis Adriaan ,  VAN LOO, Pieter Fokko ,  KLOOSTER, Rinse

    IPC分类号： C07K16/46

    摘要： The present invention addresses the problem of providing a novel drug for the prevention of autoimmune diseases, the suppression of the progression of the symptoms of autoimmune diseases, the suppression of the recurrence of autoimmune diseases, or the treatment of autoimmune diseases. As a result of diligent investigation, the inventors of the present invention have focused on PD-1/CD3 bispecific antibodies as substances that can solve the abovementioned problem and have confirmed that said bispecific antibodies make it possible to achieve pharmaceuticals that reduce the occurrence of the adverse effects known as infusion-related reaction and cytokine release syndrome. In addition, the inventors have confirmed that said bispecific antibodies allow for interaction between PD-1 and its ligand PD-L1 and have discovered that said feature contributes to enhanced and sustained activity.

    BISPECIFIC ANTIBODY
    5.
    发明公开
    BISPECIFIC ANTIBODY 审中-公开

    公开(公告)号：EP3693013A1

    公开(公告)日：2020-08-12

    申请号：EP18865322.4

    申请日：2018-10-05

    申请人： Ono Pharmaceutical Co., Ltd.

    发明人： SHIBAYAMA, Shiro ,  TEZUKA, Tomoya

    IPC分类号： A61K39/395 ,  A61P37/06 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N15/13

    摘要： The present invention addresses the problem of providing a novel medical agent for prevention of auto-immune diseases, inhibition of symptom progression thereof, inhibition of recurrence thereof, or treatment thereof. As a result of conducting extensive studies, the inventors of the present invention have focused attention on PD-1/CD19 bispecific antibody as a substance with the potentiality of solving the problem, and have achieved the present invention. The PD-1/CD19 bispecific antibody according to the present invention exhibits growth-inhibitory action and immunoglobulin production inhibitory action against activated B cells, and also has inhibitory action against production of cytokine from memory T cells.

    BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF
    6.
    发明公开
    BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF 有权
    VERBINDUNG MIT BASISCHEN GRUPPEN UND DEREN VERWENDUNG

    公开(公告)号：EP1961744A1

    公开(公告)日：2008-08-27

    申请号：EP06832893.9

    申请日：2006-11-17

    申请人： ONO PHARMACEUTICAL CO., LTD.

    发明人： KOKUBO, Masaya ,  OCHIAI, Hiroshi ,  TAKAOKA, Yoshikazu ,  SHIBAYAMA, Shiro

    IPC分类号： C07D233/64 ,  A61K31/417 ,  A61K31/4178 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/55

    CPC分类号： C07D403/12 ,  C07D233/64 ,  C07D401/12 ,  C07D403/14 ,  C07D471/10 ,  C07D498/10

    摘要： A compound represented by general formula (I):

    a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac /vascular disease(for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

    摘要翻译： 由通式（I）表示的化合物：其盐，其溶剂合物或其前药，其中所有符号如本说明书中所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗剂 CXCR4介导的疾病，例如炎症和免疫疾病（例如类风湿性关节炎，关节炎，全身性红斑狼疮，视网膜病变，黄斑变性，肺纤维化，移植器官排斥反应等），过敏性疾病，感染（例如人类免疫缺陷 病毒感染，获得性免疫缺陷综合征等），精神神经病，脑疾病，心脏/血管疾病（例如动脉硬化，心肌梗死，心动过速，脑梗死，慢性动脉闭塞性疾病等），代谢疾病和癌性疾病 （例如癌症，癌症转移等），癌性疾病或感染的预防和/或治疗剂， 或再生治疗剂。

    NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF
    7.
    发明公开
    NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF 审中-公开
    NEER POLYPEPTIDE，DAFÜRKODIERENDE cDNA UND DEREN VERWENDUNG

    公开(公告)号：EP1104771A1

    公开(公告)日：2001-06-06

    申请号：EP99935092.9

    申请日：1999-08-06

    申请人： ONO PHARMACEUTICAL CO., LTD.

    发明人： FUKUSHIMA, Daikichi ,  SHIBAYAMA, Shiro ,  TADA, Hideaki

    IPC分类号： C07K14/47 ,  C07K16/18 ,  C12N15/12 ,  C12P21/02 ,  A61K38/17

    CPC分类号： C07K14/47 ,  A61K38/00

    摘要： A new human polypeptide, a cDNA encoding the same and a pharmaceutical use of it.
    The polypeptides of the present invention possess hematopoiesis regulating activity, tissue generation/regeneration activity, activin/inhibin activity, chemotactic/chemokinetic activity, hemostatic and thrombolytic activity, and receptor/ligand activity, therefore, they are expected to be useful for prevention and/or treatment of various diseases.

    摘要翻译： 新的人多肽，编码它的cDNA及其药学用途。 本发明的多肽具有造血调节活性，组织生成/再生活性，激活素/抑制素活性，趋化性/动力学活性，止血和溶栓活性以及受体/配体活性，因此，预期它们可用于预防和/ 或治疗各种疾病。

    DUAL-SPECIFIC PROTEIN
    8.
    发明公开
    DUAL-SPECIFIC PROTEIN 审中-公开

    公开(公告)号：EP4011918A1

    公开(公告)日：2022-06-15

    申请号：EP20849041.7

    申请日：2020-08-07

    申请人： ONO Pharmaceutical Co., Ltd.

    发明人： SHIBAYAMA, Shiro ,  TEZUKA, Tomoya

    IPC分类号： C07K16/46 ,  A61K39/395 ,  A61P37/02 ,  A61P37/06 ,  C07K16/28 ,  C12N15/13

    摘要： The present invention addresses the problem of providing a new drug that, with respect to autoimmune diseases or blood cancer, is for preventing, suppressing the advance of symptoms, suppressing recurrence, or treating such diseases. The inventors of the present invention conducted extensive studies, and came to focus on a PD-1/CD4 dual-specific protein as a substance that can solve the foregoing problem, leading to completion of the present invention. The PD-1/CD4 dual-specific protein according to the present invention is configured to reduce the induction of generation or release of cytokine that occurs when the protein is administered. As a result, it can be expected that infusion reaction or cytokine release syndrome that could occur upon administration of the protein is suppressed.